Abstract
Refractory or resistant hypertension is conventionally defined as systolic or diastolic blood pressure that remains uncontrolled despite sustained therapy with at least three different classes of antihypertensive agents. Refractory hypertension is estimated to affect less than 5% of the general population with hypertension; however, its prevalence increases with increasing severity of blood pressure. Patients presenting with refractory hypertension usually have progressed from mild, to moderate, to severe hypertension because of lack of or inadequate treatment. Other common contributing factors include obesity, medical nonadherence, suboptimal medical regimens, excessive dietary salt ingestion, secondary forms of hypertension, sleep apnea, and ingestion of substances that interfere with treatment. Combination therapy that includes appropriate doses of a diuretic is recommended for treatment of refractory hypertension. Use of fixed-dose combinations enhances compliance through cost savings, more convenient dosing, and reduced pill burdens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Materson BJ, Reda DJ, Cushman WC, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Anti-Hypertensive Agents: Results of combination anti-hypertensive therapy after failure of each of the components. J Human Hypertens 1995, 9:791–796.
Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:155–1762. This paper the discusses the results of the HOT trial, the largest prospective treatment trial of hypertension. The results indicate that there are benefits of aggressive blood pressure reduction with use of combination therapy.
Moser M: Current recommendations for initial therapy in hypertension: are they still valid? Am J Hypertens 1998, 11:69S-72S.
Schwartz GL, Sheps SG: A review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Curr Opin Cardiol 1999, 14:161–168.
Yakovlevitch M, Black HR: Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991, 151:1786–1792.
Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? Ann Intern Med 1994, 121:289–300.
Jee SH, HE J, Whelton PK, et al.: The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999, 33:647–652. This article analyzes the published long-term trials that have evaluated the effects of caffeine ingestion on blood pressure.
Omvik P: How smoking affects blood pressure. Blood Press 1996, 5:71–77.
Cushman WC: Alcohol and blood pressure. In In Hypertension Primer Second Edition: The Essentials of High Blood Pressure. Edited by Izzo JL, Black HR. Dallas: American Heart Association; 1999:263–265.
Palatini P, Dorigatti F, Roman E, et al.: White-coat hypertension: a selection bias? J Hypertens 1998, 16:977–984. White-coat hypertension among a large cohort of patients with presumed hypertension is evaluated. The results indicate that white-coat hypertension may be overdiagnosed if based on a single ambulatory monitoring session.
Wright JC, Looney SW: Prevalence of positive Osler’s manoeuver in 3387 persons screened for the Systolic Hypertension in the Elderly Program (SHEP). J Hum Hypertens 1997, 11:285–289.
Zuscke CA, Pettyjohn FS: Pseudohypertension. South Med J 1995, 88:1185–1190.
Fletcher EC: The relationship between systemic hypertension and obstructive sleep apnea: facts and theory. Am J Med 1995, 98:118–128.
Wosnop CJ, Naughton MJ, Barter CE: The prevalence of obstructive sleep apnea in hypertensives. Am J Respir Crit Care Med 1998, 157:111–115.
Report of the NHBLI Working Group. Management of patient compliance in the treatment of hypertension. Hypertension 1982, 4:415–423.
Shea S, Misra D, Ehrlich MH, et al.: Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992, 327:776–781.
Lang T: Social and economic factors as obstacles to blood pressure control. Am J Hypertens 1998, 11:900–902.
Karakoff LR: Hypertension specialists: ready or not, here we come. Am J Hypertens 1999, 12:242–243.
Shmkets RA, Warnock DG, Bositis CM, et al.: Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994, 79:407–404.
Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11-betahydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262–265.
Mune T, Rogerson FM, Nikkila H, et al.: Human hypertension caused by mutations in the kidney isozyme of 11-betahydroxysteroid dehydrogenase. Nat Genet 1995, 10:394–399.
Norton GR, Woodiwiss AJ, Harford C, et al.: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999, 12:563–571.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alper, A.B., Calhoun, D.A. Contemporary management of refractory hypertension. Current Science Inc 1, 402–407 (1999). https://doi.org/10.1007/s11906-999-0055-0
Issue Date:
DOI: https://doi.org/10.1007/s11906-999-0055-0